The investments are made via Korys, the investment maatschappij van de Colruyts. Via the investeringsfonds OMX Europe Venture Fund, the Colruyt family invests in the same way with the Franse investeringsbedrijf Mérieux Equity Partners in innovative gezondheidszorg.
Now that fund is in the Franse biotechbedrijf Mablink. That was 31 million euros in new capital orders. The money must serve as a new risk treatment on the market. Mablink works specifically on a new generation of cancer genes in the middle, for patients who cannot be treated in the long term.
